Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm study of subcutaneous efgartigimod PH20 in pediatric generalized myasthenia gravis
MOH_2024-11-18_013740Phase 3Not yet recruiting
- Sponsor
- argenx
- Start
- Oct 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoint: Confirmation of an appropriate pediatric dose of subcutaneous efgartigimod PH20. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on MOH_2024-11-18_013740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-18_013740.